{
    "2020-08-09": [
        [
            {
                "time": "",
                "original_text": "【浙商医药|周报】A+H已成为大势，药筛CRO不断突破行业天花板",
                "features": {
                    "keywords": [
                        "浙商医药",
                        "A+H",
                        "药筛CRO",
                        "行业天花板"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【平安生物】港股医药策略报告：优质标的集结，长期配置优选",
                "features": {
                    "keywords": [
                        "平安生物",
                        "港股医药",
                        "优质标的",
                        "长期配置"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "港股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}